ciglitazone

Ciglitazone is a synthetic small molecule and the prototypical compound of the thiazolidinedione (glitazone) class, developed by Takeda Pharmaceuticals in the early 1980s as an antidiabetic agent[2][3][7]. It acts as a potent and selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), with an EC50 of approximately 3.0 μM[2][4][5]. Through PPARγ activation, ciglitazone exerts antihyperglycemic effects in animal models, increases adipogenesis, decreases angiogenesis and osteoblastogenesis, and modulates inflammatory pathways including nuclear factor-kappaB signaling[1][2]. It also inhibits vascular endothelial growth factor (VEGF) production and has demonstrated anti-cancer activity in preclinical studies by sensitizing tumor cells to TRAIL-induced apoptosis via both PPARγ-dependent and independent mechanisms[6]. Although it was never marketed or approved for clinical use due to limited efficacy or safety concerns observed during development, ciglitazone served as a lead compound for later thiazolidinediones such as pioglitazone. Its potential indications included diabetes mellitus and ovarian hyperstimulation syndrome; however, its development was discontinued at phase II for diabetes mellitus in Japan[7].